NPCE at a glance
NeuroPace Inc (NPCE, SEC CIK 1528287) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), NeuroPace Inc (NPCE) reported revenue of $100.0 million (up 25.1% from FY2024) and a net loss of $21.5 million. Diluted EPS was -$0.66.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding NeuroPace Inc (NPCE) shares worth $141.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $100.0M
- +25.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $141.8M · +0 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $22.8M, up 17% YoY from $19.5M, driven by higher RNS System unit sales
- Gross margin 82.8% vs 83.1% YoY, reflecting higher material costs partly offset by favorable pricing
- Loss from continuing operations $5.1M vs $8.2M YoY; net loss $6.2M vs $8.7M
- Cash, equivalents and short-term investments $51.7M; outstanding debt $59.0M at June 30, 2026
- FDA deemed PMA-S not approvable; additional information requested for generalized epilepsy label expansion
Risk Factors
- Newly added manufacturing risk: QMSR superseded QSR on February 2, 2026, creating updated compliance requirements
- Most materially updated regulatory risk: FDA staffing changes may delay review of indication-expansion submissions for IGE and ages 12–17
- Compliance risk: Failure to comply with federal and state fraud-and-abuse laws could trigger substantial penalties
- Operational risk: Single-source suppliers Micro Systems Technologies and Integer provide critical components including batteries
- Financial risk: Term Loan Agreement contains financial maintenance covenants, with noncompliance potentially accelerating repayment
AI summary of the NPCE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results released for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and investor-relevant operating details
Item EX-99.1: Item EX-99.1
- Q2 revenue $22.8M, up 17%; RNS revenue $22.5M, up 21.3%, signaling continued adoption in focal epilepsy
- Net loss narrowed to $6.2M from $10.0M; Adjusted EBITDA loss improved to $2.8M from $4.9M
Item 7.01: Regulation FD Disclosure
- FDA found RNS System indication expansion not approvable in current form
- Requested additional clinical evidence for medication-resistant IGE patients with GTC seizures
Item EX-99.1: Item EX-99.1
- FDA found the IGE PMA supplement not approvable in its current form, delaying potential RNS indication expansion
- NeuroPace plans a Submission Issue Request and additional NAUTILUS clinical evidence to address FDA questions
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected Lisa Andrade and Scott Huennekens as Class II directors through the 2029 annual meeting
- Andrade received 15,194,450 votes for versus 6,024,133 withheld, indicating notable shareholder reservation
AI summaries of NPCE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NPCE
Don't miss the next NPCE filing
- Alerts as it files. A push when NPCE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NPCE, by share count.
- Ask anything. An AI agent that reads every NPCE filing and answers with sources.
NPCE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Morrell Martha | F | Sep 24, 2026 | 335 | $13.97 |
| Williams Patrick F. | F | Sep 20, 2026 | 1,162 | $14.28 |
| Becker Joel | F | Sep 3, 2026 | 1,310 | $14.75 |
| Becker Joel | F | Aug 27, 2026 | 1,126 | $14.13 |
| Morrell Martha | F | Aug 27, 2026 | 358 | $14.13 |
| Morrell Martha | F | Jun 24, 2026 | 335 | $16.22 |
| Geiger Uri | A | Jun 19, 2026 | 789 | $15.63 |
| Kumar Rakhi | A | Jun 19, 2026 | 989 | $15.63 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $79.9M | $100.0M |
| Gross Profit | - | $59.1M | $77.2M |
| Operating Income | - | -$21.7M | -$16.3M |
| Net Income | - | -$27.1M | -$21.5M |
| Gross Margin | - | 73.9% | 77.2% |
| Op. Margin | - | -27.1% | -16.3% |
| Net Margin | - | -34.0% | -21.5% |
| Balance Sheet | |||
| Total Assets | $107.7M | $94.6M | $105.6M |
| Equity | $20.7M | $8.0M | $19.0M |
| ROE | - | -338.7% | -112.8% |
| Per Share | |||
| EPS | - | $-0.93 | $-0.66 |
| Cash Flow | |||
| Operating CF | - | -$17.9M | -$11.0M |
| CapEx | - | $306K | $332K |
Source: XBRL data in NeuroPace Inc (NPCE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NPCE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $141.8M |
| Q1 2026 | 22 | $110.4M |
| Q4 2025 | 19 | $137.0M |
| Q3 2025 | 17 | $84.8M |
| Q2 2025 | 20 | $89.0M |
| Q1 2025 | 15 | $63.6M |
| Q4 2024 | 10 | $27.7M |
| Q3 2024 | 7 | $8.3M |
- BlackRock+131.3K (+6%)
- D.E. Shaw & Co+117.5K (+269%)
- Vanguard Capital Management LLC+103.4K (+9%)
- Morgan Stanley+87.6K (+3%)
- State Street Corp+52.6K (+11%)
- Renaissance Technologies LLC−62.6K (-36%)
- Two Sigma Investments−43.9K (-59%)
- Goldman Sachs Group−25.8K (-15%)
- Millennium Management−10.0K (-25%)
- Bank of America Corp−4.4K (-18%)
- U.S. Bancorp−13
Source: 13F-HR filings on SEC EDGAR (aggregated from 132 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NPCE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
NPCE SEC filings: frequently asked questions
Which institutions hold NPCE stock?
As of June 30, 2026, the largest NeuroPace Inc (NPCE) holders among the 13F filers tracked by SignalX were Morgan Stanley ($42.2 million), BlackRock ($39.4 million), Vanguard Capital Management LLC ($19.5 million), FMR LLC (Fidelity) ($8.8 million), State Street Corp ($8.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NPCE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), NeuroPace Inc (NPCE) reported revenue of $100.0 million (up 25.1% from FY2024) and a net loss of $21.5 million. Diluted EPS was -$0.66. The figures come from the XBRL data in the 10-K.
What did NPCE report in its latest 8-K?
NeuroPace Inc (NPCE) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results released for quarter ended June 30, 2026.
What are the latest NPCE SEC filings?
NeuroPace Inc (NPCE) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on September 25, 2026.
What is NPCE's SEC CIK number?
NeuroPace Inc (NPCE)'s SEC Central Index Key (CIK) is 1528287. EDGAR lists every NPCE filing under that number.
Ask anything about NPCE
The research agent reads NPCE's filings, financials, insider trades and 13F holders, then answers with sources.